MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Market Wire - Pharmaceuticals and Biotech' source. Thu, 09 Feb 2012 01:31:33 +0100 http://www.medworm.com/index.php?rid=5562797&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D838066%26tsource%3D3 LEIDEN, NETHERLANDS (MARKET WIRE) Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it has redeemed part of its EUR8.4 million convertible bond. A total of 38.9 million shares were issued to the bondholders under the terms and conditions of the bond, serving as a pre-installment for the February 6, 2012 redemption and interest payment, with the balance to be held for subsequent redemptions, if elected to be paid in shares. It is expected that the shares will be admitted to listing and trading on Euronext Amsterdam on January 9, 2012. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5562797 Fri, 06 Jan 2012 06:06:00 +0100 5562797 http://www.medworm.com/index.php?rid=5546205&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D836365%26tsource%3D3 TORONTO, ONTARIO (MARKET WIRE) Cynapsus Therapeutics (TSX VENTURE: CTH) advises that Noverra Research, a provider of independent equity research, has released a comprehensive report that describes Cynapsus' business along with its recommendations. This 10-page report includes detailed information about the Parkinson's disease market, Cynapsus' APL-130277 project and strategy, as well as other company-related information and associated risks. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5546205 Wed, 28 Dec 2011 22:00:00 +0100 5546205 http://www.medworm.com/index.php?rid=5516792&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D834299%26tsource%3D3 MECHELEN, BELGIUM (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5516792 Mon, 19 Dec 2011 17:27:00 +0100 5516792 http://www.medworm.com/index.php?rid=5507403&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D833769%26tsource%3D3 SEATTLE, WA (MARKET WIRE) Integrated Diagnostics announced today that researchers from the company and the California Institute of Technology (Caltech) will receive a Point-of-Care Diagnostics grant through Grand Challenges in Global Health, an initiative created by the Bill & Melinda Gates Foundation that seeks to engage creative minds across scientific disciplines -- including those who have not traditionally taken part in health research -- to work on solutions that could lead to breakthrough advances for those in the developing world. Jim Heath, Ph.D., co-founder and Board member, Integrated Diagnostics; (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5507403 Fri, 16 Dec 2011 18:04:00 +0100 5507403 http://www.medworm.com/index.php?rid=5460540&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D828130%26tsource%3D3 SAN DIEGO, CA (MARKET WIRE) Quidel Corporation (NASDAQ: QDEL), a leading provider of diagnostic testing solutions, announced today that it has received the CE Mark for its Sofia Strep A FIA for use with its Sofia Analyzer. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5460540 Thu, 01 Dec 2011 18:45:00 +0100 5460540 http://www.medworm.com/index.php?rid=5460541&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D828165%26tsource%3D3 VANCOUVER, BRITISH COLUMBIA (MARKET WIRE) RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCBB: REPCF) is pleased to report that David Hall, CEO will be presenting at the LD MICRO Growth Conference on Thursday, December 8th at 3:30pm PDT. Mr. Hall's presentation will introduce RepliCel's autologous hair cell replication technology to over 150 institutions attending this two-day conference where some of the fastest growing companies on the OTC, NASDQ and NYSE are featured. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5460541 Thu, 01 Dec 2011 18:30:00 +0100 5460541 http://www.medworm.com/index.php?rid=5451033&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D826320%26tsource%3D3 BELLINGHAM, WA (MARKET WIRE) IMCD Benelux, part of the IMCD Group, and Sweet Green Fields LLC (SGF) have signed a partnership for the pan-European distribution of SGF's line of stevia extracts. IMCD's extensive knowledge of the European market and technical expertise proved to be a critical factor in the appointment. The deal follows the long awaited EU approval for the use of steviol glycosides as a non-calorific sweetener in the European market. The regulation was formally adopted on November 11 and will go into effect as of December 2, 2011. A leading supplier and US based stevia producer, SGF has a complete (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5451033 Mon, 28 Nov 2011 18:00:00 +0100 5451033 http://www.medworm.com/index.php?rid=5433576&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D824952%26tsource%3D3 CONSHOHOCKEN, PA (MARKET WIRE) NuPathe Inc. (NASDAQ: PATH), an emerging biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that Jane Hollingsworth, chief executive officer, will present a company overview at the Piper Jaffray 23rd Annual Healthcare Conference on Wednesday, November 30, 2011, at 4:00 p.m. EST. The conference is being held at The New York Palace Hotel in New York, NY. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5433576 Tue, 22 Nov 2011 18:30:00 +0100 5433576 http://www.medworm.com/index.php?rid=5402157&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D821131%26tsource%3D3 ORLANDO, FL (MARKET WIRE) The ISAR group, world leading cardiology researchers based in Munich, Germany, today simultaneously presented and published results of the 1,721-patient randomized, double-blind, active-controlled, multicenter ISAR-REACT-4 clinical trial in patients with evidence of evolving infarction (heart attack) undergoing percutaneous coronary interventions (PCI). The Medicines Company announced that the late breaking results were presented at the American Heart Association Scientific Sessions 2011 here today and published in The New England Journal of Medicine. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5402157 Sun, 13 Nov 2011 17:47:00 +0100 5402157 http://www.medworm.com/index.php?rid=5391199&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D820518%26tsource%3D3 CALGARY, ALBERTA (MARKET WIRE) Editor's Note: There is a photo and a video associated with this release. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5391199 Thu, 10 Nov 2011 19:08:00 +0100 5391199 http://www.medworm.com/index.php?rid=5350496&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D814210%26tsource%3D3 BAGSVAERD, DENMARK (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5350496 Thu, 27 Oct 2011 05:49:00 +0100 5350496 http://www.medworm.com/index.php?rid=5276828&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D804966%26tsource%3D3 ALBUQUERQUE, NM (MARKET WIRE) Radiation phobia, the belief that exposure to a small dose of radiation is dangerous, persists because media outlets and government agencies continue to fan the flames of fear in the public despite a wealth of research to the contrary. Radiation phobia-related harm is a significant risk that should be considered during radiological emergencies such as the incident at the Fukushima nuclear plant in Japan. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5276828 Mon, 03 Oct 2011 17:11:00 +0100 5276828 http://www.medworm.com/index.php?rid=5263567&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D803965%26tsource%3D3 TORONTO, ONTARIO (MARKET WIRE) Asia Packaging Group Inc. (TSX VENTURE: APX) ("Asia Packaging" or the "Company") is pleased to announce its interim financial statements for the three-month period ending June 30, 2011. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5263567 Thu, 29 Sep 2011 18:45:00 +0100 5263567 http://www.medworm.com/index.php?rid=5252727&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D802104%26tsource%3D3 NEW YORK, NY (MARKET WIRE) IntelliCell BioSciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC) ("IntelliCell" or the "Company"), a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose-derived adult stem cells, announced today that it has executed an exclusive supply and sale agreement with Millipore Corporation, a global leader in innovative tools and technologies for bio-manufacturing and life science research, to sell and distribute the guava(R) flow cytometry platform into the area of SVF. This collaboration will streamline the development of IntelliCell's tissue (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5252727 Mon, 26 Sep 2011 11:00:00 +0100 5252727 http://www.medworm.com/index.php?rid=5252728&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D802087%26tsource%3D3 BEVERLY, MA (MARKET WIRE) Cellceutix Corporation (OTCQB: CTIX) (PINKSHEETS: CTIX) (the "Company"), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, today released pictures of its mice study with KM-133, the Company's small molecule acting on the principles of immune stimulation and PRINS reduction as a new treatment for psoriasis. The pictures are available for viewing at http://www.cellceutix.com/product-candidates/km-133---psoriasis-compound.html. The pictures show a dramatic response to treatment with KM-133. In the studies 100% of the mice (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5252728 Mon, 26 Sep 2011 10:30:00 +0100 5252728 http://www.medworm.com/index.php?rid=5228854&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D799770%26tsource%3D3 BERLIN (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5228854 Mon, 19 Sep 2011 08:10:00 +0100 5228854 http://www.medworm.com/index.php?rid=5176853&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D793470%26tsource%3D3 BEVERLY, MA and TORONTO (MARKET WIRE) Hamilton Thorne Ltd. (TSX-V: HTL) ("Hamilton Thorne" or the "Company"), a leading provider of advanced laser systems for the regenerative medicine, fertility and stem cell research markets, today announced the closing of the first tranche of its previously announced non-brokered private placement of common shares ("Common Shares") of the Company. On closing, the Company issued an aggregate of 12,469,500 Common Shares at a price of CDN$0.20 per Common Share (the "Offering Price") for aggregate gross proceeds of US$2.55 million. An aggregate of 11,980,500 Common Shares, representing aggregate (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5176853 Tue, 30 Aug 2011 21:07:00 +0100 5176853 http://www.medworm.com/index.php?rid=5176854&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D793473%26tsource%3D3 VANCOUVER, BRITISH COLUMBIA (MARKET WIRE) Ondine Biomedical Inc. (the "Company" or "Ondine") (TSX: OBP)(AIM: OBP) announced that at the annual general meeting of the shareholders and special meeting of securityholders of Ondine (collectively, the "Meeting") held today, the securityholders (the "Securityholders") approved the previously announced plan of arrangement (the "Arrangement") pursuant to which 0902337 B.C. Ltd. (the "Purchaser"), a private company whose sole shareholder is Carolyn Cross, Chairman, Chief Executive Officer and a shareholder of Ondine, will acquire (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5176854 Tue, 30 Aug 2011 20:54:00 +0100 5176854 http://www.medworm.com/index.php?rid=5171703&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D792850%26tsource%3D3 PORT HUENEME, CA (MARKET WIRE) Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to announce that the National Science Foundation (NSF) has awarded Stellar's Phase IIB proposal (http://www.nsf.gov/eng/iip/sbir/phase_iib.jsp) a $498,560 grant for full implementation of commercial scale aquaculture systems for KLH (Keyhole Limpet Hemocyanin) production and development and deployment of a validated KLH-based immunogenicity assay. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5171703 Mon, 29 Aug 2011 20:05:00 +0100 5171703 http://www.medworm.com/index.php?rid=5171704&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D792865%26tsource%3D3 Discussion and Analysis ("MD&A") has been filed with the System for Electronic Document Analysis and Retrieval ("SEDAR") and will be available at www.sedar.com. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5171704 Mon, 29 Aug 2011 19:26:00 +0100 5171704 http://www.medworm.com/index.php?rid=5127784&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D788103%26tsource%3D3 SAN JOSE, CA (MARKET WIRE) Interface Masters Technologies, an industry leader and innovator in networking solutions, today announced 48 Ports of 10Gb sophisticated Hardware-based Load Balancing. Niagara 4248 completes the extensive family of fully managed appliances that are built for optimal flexibility, enabling extensive filtering capabilities, L2, L3 and L4 filtering, including User Define Byte (UDB), extensive Mirroring options, sophisticated session based traffic distribution and traffic aggregation. Niagara 4224, 4216 and 4208 are unique configurations (24, 16 and 8 port options respectively) that have been on (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5127784 Mon, 15 Aug 2011 15:22:00 +0100 5127784 http://www.medworm.com/index.php?rid=5112411&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D787270%26tsource%3D3 LUND, SWEDEN (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5112411 Thu, 11 Aug 2011 06:39:00 +0100 5112411 http://www.medworm.com/index.php?rid=5065477&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D781907%26tsource%3D3 GENEVA, SWITZERLAND (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5065477 Wed, 27 Jul 2011 05:11:00 +0100 5065477 http://www.medworm.com/index.php?rid=5058943&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D780847%26tsource%3D3 IRVINE, CA (MARKET WIRE) BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental laser manufacturer and distributor, today announced that the Company is now taking orders for its new state-of-the-art BIOLASE DaVinci Imaging™ dental imaging devices for delivery in Q-3. The diagnostic capabilities of the BIOLASE DaVinci Imaging products complement the biological, minimally invasive dental treatment solutions offered by the BIOLASE Laser division. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5058943 Mon, 25 Jul 2011 13:00:00 +0100 5058943 http://www.medworm.com/index.php?rid=5058942&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D780822%26tsource%3D3 TEMECULA, CA (MARKET WIRE) FFF Enterprises, Inc., the nation's largest and most trusted distributor of flu vaccine, announced today that shipments of the seasonal flu vaccine have begun, in support of a nationwide rollout of annual influenza immunization programs. The unusually early July shipment date is made possible by the exceptional performance of FFF's manufacturing partners. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5058942 Mon, 25 Jul 2011 13:00:00 +0100 5058942 http://www.medworm.com/index.php?rid=5043257&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D780280%26tsource%3D3 SOUTH SAN FRANCISCO, CA (MARKET WIRE) CompareNetworks, Inc. a global online B2B media company, announced today they've hired Brian Cowley as CEO. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5043257 Thu, 21 Jul 2011 17:24:00 +0100 5043257 http://www.medworm.com/index.php?rid=5043258&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D780302%26tsource%3D3 VANCOUVER, BRITISH COLUMBIA (MARKET WIRE) Pyng Medical Corp. (the "Company") (TSX VENTURE: PYT) announced today that the T-POD(R) has been chosen by Yorkshire Ambulance Service NHS Trust, through Pyng's exclusive dealer in the UK, Lewis's Medical Supplies, as their standardized pelvic stabilization device. Yorkshire Ambulance NHS is one of 12 Ambulance Trusts in the UK. After undergoing an extensive search and trial period on available pelvic stabilization products in the market, the T-POD(R) was chosen for Yorkshire Ambulance's frontline fleet of ambulances. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5043258 Thu, 21 Jul 2011 17:17:00 +0100 5043258 http://www.medworm.com/index.php?rid=5001981&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D775634%26tsource%3D3 CLEVELAND, OH (MARKET WIRE) Verantis Corporation, a global provider of turnkey environmental and process solutions for industrial plants, announced it has received a major project award to supply an emission control system for a large scale sterilization process. A major supplier of medical devices in the U.S. has expanded their operations and required a system for high-efficiency control of ethylene oxide emissions from the on-site sterilization chambers. Our system is also capable of handling emergency releases from the sterilant storage area. Verantis will provide a complete engineered absorption system including (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=5001981 Thu, 07 Jul 2011 15:33:00 +0100 5001981 http://www.medworm.com/index.php?rid=4979090&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D773418%26tsource%3D3 WASHINGTON, DC (MARKET WIRE) Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- If one is looking for big, then BIO 2011 is the place to be. With an estimated 14,000 in attendance, thousands streamed inside as the doors were opened to the BIO 2011 Exhibition on Tuesday, June 28. While the annual 2011 international BIO conference (June 27-30, 2011, Washington Convention Center) officially began on Monday, Tuesday was opening day for the popular Exhibition. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4979090 Wed, 29 Jun 2011 22:17:00 +0100 4979090 http://www.medworm.com/index.php?rid=4979091&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D773422%26tsource%3D3 ROCK HILL, SC (MARKET WIRE) 3D Systems (NYSE: DDD) today announced that Quickparts® recently assisted Eye-Com Corporation in the design and development of Eye-Com's innovative EC7T eye tracking system. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4979091 Wed, 29 Jun 2011 21:47:00 +0100 4979091 http://www.medworm.com/index.php?rid=4963587&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D771297%26tsource%3D3 SAN DIEGO, CA (MARKET WIRE) With type 2 diabetes now dramatically increasing in European countries where systematic screening is not consistently or routinely employed, researchers are exploring how early detection and intervention can help increase control of the disease and reduce life-threatening complications such as cardiovascular disease. Two such studies presented data today at the American Diabetes Association's 71st Scientific Sessions®. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4963587 Sat, 25 Jun 2011 15:30:00 +0100 4963587 http://www.medworm.com/index.php?rid=4948053&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D769963%26tsource%3D3 REYKJAVIK, ICELAND and ISAFJORDUR, ICELAND (MARKET WIRE) Kerecis Limited, the emerging tissue-regeneration company, today announced that its Chairman G. Fertram Sigurjonsson will make a presentation at Elsevier's IN3 East Investor Conference in Boston (Wednesday, June 22, 8:35 a.m., Hyatt Regency Boston). (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4948053 Tue, 21 Jun 2011 00:19:00 +0100 4948053 http://www.medworm.com/index.php?rid=4925708&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D766624%26tsource%3D3 ROCKVILLE, MD (MARKET WIRE) MarketResearch.com has announced the addition of the new report "Tele-Health Monitoring: Market Shares, Strategies, and Forecasts, Worldwide, 2011 to 2017," to their collection of Information Technology market reports. For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=6402708 (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4925708 Tue, 14 Jun 2011 15:08:00 +0100 4925708 http://www.medworm.com/index.php?rid=4925709&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D767551%26tsource%3D3 SUNNYVALE, CA (MARKET WIRE) Amarantus BioSciences, Inc. (OTCBB: AMBS), a California-based biotechnology company developing first-in-class proteins, today announced the successful completion of the Company's capital restructuring initiatives, including a 25-for-1 forward stock split (the "Forward Stock Split"), which was previously approved by its stockholders and announced on June 2, 2011. According to FINRA's confirmation, the Forward Stock Split became effective on June 13, 2011 (the "Effective Date"). As of the Effective Date, and as a result of the Forward Stock Split, there are approximately 67,000,000 shares (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4925709 Tue, 14 Jun 2011 15:06:00 +0100 4925709 http://www.medworm.com/index.php?rid=4925711&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D766667%26tsource%3D3 TUSTIN, CA (MARKET WIRE) The European Patent Office (EPO) has granted Epinex Diagnostics the patent for the first 'Rapid Test for Glycated Albumin.' The patent (EP 1664783) is for Epinex' G1A™ Rapid Diabetes Monitoring Index Test, a test with the potential to improve the way diabetes is managed through monthly glycation monitoring at the point-of-care (POC). (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4925711 Tue, 14 Jun 2011 15:00:00 +0100 4925711 http://www.medworm.com/index.php?rid=4925710&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D767176%26tsource%3D3 SUNNYVALE, CA (MARKET WIRE) Now celebrating its 15th anniversary, ProTrials Research™, Inc. (www.protrials.com), a leader in the clinical research organization (CRO) industry, continues its rapid expansion with the addition of international studies in Spain and Italy and the completion of its company headquarters relocation to Sunnyvale, CA. Recognized as one of the top women-owned businesses in Silicon Valley and one of a select few U.S.-based CROs operated by women, ProTrials has now successfully completed more than 350 clinical trials conducted throughout North America, Europe and the Pacific Rim. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4925710 Tue, 14 Jun 2011 15:00:00 +0100 4925710 http://www.medworm.com/index.php?rid=4879752&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D762202%26tsource%3D3 GHENT, BELGIUM (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4879752 Tue, 31 May 2011 16:14:00 +0100 4879752 http://www.medworm.com/index.php?rid=4857029&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D760658%26tsource%3D3 LYMAN, SC (MARKET WIRE) Southern Home Medical Equipment, Inc. (PINKSHEETS: SHOM), a holding company providing healthcare services, staffing and durable medical equipment to medical institutions, announced today that President and CEO Jeff Sarvis and Board Director Jerry Overcash will host a conference call for all shareholders, potential investors and other interested parties on Thursday, May 26, 2011 at 4:15 pm Eastern Time. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4857029 Wed, 25 May 2011 17:01:00 +0100 4857029 http://www.medworm.com/index.php?rid=4857030&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D760665%26tsource%3D3 ALISO VIEJO, CA (MARKET WIRE) Between demographic changes and other data, more than 40 percent of a typical medical device or pharmaceutical manufacturer's provider records have missing or inaccurate information. Adding to the problem, upwards of 30-50 percent of those provider records are duplicated across customer relationship management (CRM) software and other internal databases. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4857030 Wed, 25 May 2011 16:54:00 +0100 4857030 http://www.medworm.com/index.php?rid=4844466&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D759206%26tsource%3D3 BUENA PARK, CA (MARKET WIRE) GreenGro Technologies, Inc.'s CEO, David L. Rudat, clarified the company's strategic focus today, stating that GreenGro Technologies, Inc. (PINKSHEETS: GRNH) is specifically focused on product development in domestic and international markets, and development of new technologies for agriculture worldwide through its manufacturing capabilities. "Our company has a specific focus and is excited about the technological advancements we are developing," said Rudat. The company has developed 3 additional vertical wall units to its product line, and plans to open its first hydroponics store carrying (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4844466 Fri, 20 May 2011 20:53:00 +0100 4844466 http://www.medworm.com/index.php?rid=4835022&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D758372%26tsource%3D3 BOSTON, MA and MORRISTOWN, NJ (MARKET WIRE) BioAegis Therapeutics announced today that they have entered into an Exclusive Option Agreement with Brigham and Women's Hospital for technology based on research of Dr. Thomas Stossel, Director, Translational Medicine at Brigham and Women's Hospital, and American Cancer Society Professor of Medicine, Harvard Medical School and collaborators at Massachusetts General Hospital, University of Pennsylvania, Beth Israel Deaconess Medical Center and BloodCenter of Wisconsin. This exclusive option to a worldwide license encompasses therapeutic and diagnostic uses of the technology for human and (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4835022 Thu, 19 May 2011 14:23:00 +0100 4835022 http://www.medworm.com/index.php?rid=4816184&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D756036%26tsource%3D3 ALEXANDRIA, VA (MARKET WIRE) Key medical organizations involved in the treatment of diabetes, organizations advocating for the rights of children with disabilities, child care advocates, the United States Department of Justice, the California Department of Education, and the California School Boards Association filed friend of the court briefs in the California Supreme Court this week in support of the American Diabetes Association's efforts to ensure that all of California's students with diabetes can access insulin and remain safe at school. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4816184 Fri, 13 May 2011 14:07:00 +0100 4816184 http://www.medworm.com/index.php?rid=4791723&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D753261%26tsource%3D3 MONTREAL, QUEBEC, CANADA (MARKET WIRE) ProMetic Life Sciences Inc. ("ProMetic") (TSX: PLI) will host its Annual Meeting of Shareholders ("AGM") on Wednesday, May 18, 2011 at 10:30 a.m. (EDT) in Salon 3, Level 2 of the Centre Sheraton Montreal Hotel, located at 1201 Rene-Levesque Blvd. West, Montreal. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4791723 Fri, 06 May 2011 21:16:00 +0100 4791723 http://www.medworm.com/index.php?rid=4784742&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D752811%26tsource%3D3 PARSIPPANY, NJ (MARKET WIRE) The Medicines Company (NASDAQ: MDCO) will present at the Bank of America Merrill Lynch Health Care Conference on Thursday, May 12th, in Las Vegas beginning at 8:30am Pacific Time. Glenn Sblendorio, Executive Vice President and Chief Financial Officer, will provide a company overview. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4784742 Thu, 05 May 2011 20:45:00 +0100 4784742 http://www.medworm.com/index.php?rid=4777107&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D751315%26tsource%3D3 CAMBRIDGE, MA (MARKET WIRE) Molecular Insight Pharmaceuticals, Inc. (OTCQB: MIPIQ) (PINKSHEETS: MIPIQ), today announced that it intends to file a Form 15 with the Securities Exchange Commission (the "SEC") on or about May 13, 2011 to deregister its common stock and common stock purchase rights which are attached to and traded with shares of the common stock under the Securities Exchange Act of 1934, as amended, and to suspend its reporting obligations thereunder. On January 21, 2011, The Nasdaq Stock Market LLC filed Form 25 with the SEC to delist the Molecular Insight's common stock from the Nasdaq Global Market, (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4777107 Tue, 03 May 2011 19:30:00 +0100 4777107 http://www.medworm.com/index.php?rid=4772699&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D750825%26tsource%3D3 WEST HARTFORD, CT (MARKET WIRE) BroadcastMed, Inc.'s surgical web portal ORLive.com presents a webcast featuring simultaneous treatment of erectile dysfunction (ED) with the Coloplast Titan® Inflatable Penile Prosthesis and Stress Urinary Incontinence (SUI) with the Coloplast Virtue® Male Sling. This program will include an expert roundtable discussion of Urologists who will discuss their personal experience, surgical pearls, and the patient benefits of combining the two procedures into one surgery. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4772699 Mon, 02 May 2011 21:07:00 +0100 4772699 http://www.medworm.com/index.php?rid=4760123&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D749390%26tsource%3D3 ROCKY MOUNT, NC (MARKET WIRE) PharmStar Pharmaceuticals, Inc., (PINKSHEETS: PHAR) (the "Company"), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, today announced that it has published its financial report for the quarter ended March 31, 2011 on the OTC Markets website. The report may be found here: http://www.otcmarkets.com/stock/PHAR/financials. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4760123 Thu, 28 Apr 2011 18:56:00 +0100 4760123 http://www.medworm.com/index.php?rid=4750104&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D748448%26tsource%3D3 PHILLIPSBURG, NJ (MARKET WIRE) Avantor™ Performance Materials announced a definitive agreement to acquire POCH S.A. from Kulczyk. Completion of the sale is dependent on obtaining the necessary clearance from the Polish competition authority, and is subject to customary closing conditions. Terms of the deal were not disclosed. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4750104 Tue, 26 Apr 2011 17:59:00 +0100 4750104 http://www.medworm.com/index.php?rid=4728138&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D746645%26tsource%3D3 MECHELEN, BELGIUM (MARKET WIRE) Galapagos NV (Euronext: GLPG) announced today that its BioFocus service division has delivered a panel of validated oncology targets in its collaboration with Janssen Research & Development, a division of Janssen Pharmaceutica N.V. (Janssen). Per the agreement, Janssen retains full rights to discover, develop and commercialize novel medicines on these targets. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4728138 Wed, 20 Apr 2011 06:04:00 +0100 4728138 http://www.medworm.com/index.php?rid=4700207&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D743804%26tsource%3D3 SAN FRANCISCO, CA (MARKET WIRE) Poniard Pharmaceuticals, Inc. (NASDAQ: PARD), a biopharmaceutical company focused on innovative oncology therapies, announced today that it will seek shareholder approval of an authorization enabling its board of directors, in its discretion, to effect a reverse stock split in the range of 1-for-15 to 1-for-25 shares of common stock. The reverse stock split would provide the Company with a means to cure its minimum bid price deficiency for continued listing on The NASDAQ Capital Market, if such action becomes necessary. The authorization will be voted upon at the annual meeting of (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4700207 Tue, 12 Apr 2011 21:03:00 +0100 4700207 http://www.medworm.com/index.php?rid=4688860&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D742577%26tsource%3D3 SAN FRANCISCO, CA (MARKET WIRE) Medivation, Inc. (NASDAQ: MDVN) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time, Monday, April 11, to discuss the HORIZON Phase 3 trial results for dimebon (latrepirdine) in patients with Huntington disease. A press release will be issued at 7:30 a.m. Eastern Time Monday prior to this call. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4688860 Fri, 08 Apr 2011 21:00:00 +0100 4688860 http://www.medworm.com/index.php?rid=4672901&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D740626%26tsource%3D3 NEW YORK, NY (MARKET WIRE) Royalty Pharma announced today that it has acquired the rights to certain royalties payable on sales of Lexiscan® and Cubicin® from an undisclosed seller for a cash payment of $487 million. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4672901 Mon, 04 Apr 2011 23:23:00 +0100 4672901 http://www.medworm.com/index.php?rid=4672902&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D740625%26tsource%3D3 VANCOUVER, BRITISH COLUMBIA (MARKET WIRE) Pacgen Biopharmaceuticals Corporation (TSX VENTURE: PGA) ("Pacgen" or the "Company") announced today the issuance of an aggregate of 1,873,000 stock options to directors and officers of the Company. Each option will have an exercise price of $0.06 per share and expire no later than February 14, 2016. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4672902 Mon, 04 Apr 2011 23:00:00 +0100 4672902 http://www.medworm.com/index.php?rid=4660589&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D739534%26tsource%3D3 LENEXA, KS (MARKET WIRE) Mediware Information Systems, Inc. (NASDAQ: MEDW) today announced that it has signed a definitive purchase agreement to acquire assets of CareCentric, Inc.'s home medical equipment, home health and home infusion businesses. Mediware will acquire more than 300 new customers and the related products, services and contracts. Mediware and CareCentric expect to close the acquisition within 30 days. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4660589 Thu, 31 Mar 2011 23:36:23 +0100 4660589 http://www.medworm.com/index.php?rid=4655326&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D738800%26tsource%3D3 SAN FRANCISCO, CA (MARKET WIRE) Poniard Pharmaceuticals, Inc. (NASDAQ: PARD), a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the fourth quarter and year ended December 31, 2010. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4655326 Wed, 30 Mar 2011 21:34:42 +0100 4655326 http://www.medworm.com/index.php?rid=4655325&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D738879%26tsource%3D3 WASHINGTON, DC (MARKET WIRE) Judicial Watch, the public interest group that investigates and prosecutes government corruption, announced today that it has obtained documents from the Department of Health and Human Services regarding the controversial review of the prostate cancer treatment Provenge by the Centers for Medicare and Medicaid Services (CMS). Judicial Watch obtained the documents pursuant to a Freedom of Information Act (FOIA) lawsuit filed on January 3, 2011 (Judicial Watch v. Department of Health and Human Services (No. 11-0002)). (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4655325 Wed, 30 Mar 2011 21:34:41 +0100 4655325 http://www.medworm.com/index.php?rid=4628584&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D736666%26tsource%3D3 CAMBRIDGE, MA (MARKET WIRE) InVivo Therapeutics Holdings Corp. (OTCBB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today reported financial results for the year ended December 31, 2010. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4628584 Thu, 24 Mar 2011 21:16:05 +0100 4628584 http://www.medworm.com/index.php?rid=4628583&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D736744%26tsource%3D3 WICHITA, KS (MARKET WIRE) Pulse Systems, Inc., an industry-leading vendor of Electronic health Records (EHR) and Practice Management solutions, and Loudoun Medical Group (LMG) have signed a definitive agreement to provide 170 of their physicians with state-of-the-art Complete EHR technology. Loudoun Medical Group focuses on allowing their physicians to do what they do best: helping their community and serving their patients. LMG chose the Pulse Complete EHR solution over a system they had been using for five years due to the significant workflow advantages that exist for their physicians using the Pulse product. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4628583 Thu, 24 Mar 2011 21:16:05 +0100 4628583 http://www.medworm.com/index.php?rid=4623991&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D736141%26tsource%3D3 BOTHELL, WA (MARKET WIRE) Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today reported financial results for the fourth quarter and full year ended December 31, 2010, and highlighted recent corporate accomplishments. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4623991 Wed, 23 Mar 2011 20:56:09 +0100 4623991 http://www.medworm.com/index.php?rid=4618360&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D735617%26tsource%3D3 SAN FRANCISCO, CA (MARKET WIRE) With escalating R&D expenditures, a paucity of new drug approvals, increasing safety demands by regulators, and the loss of revenue to generics as patents expire on their blockbuster drugs, the pharmaceutical industry has turned its focus towards biotechnology. The business models that created value in the past are no longer effective in an increasingly risk-averse and competitive environment that includes governments focused on controlling healthcare costs, skittish investors, and demanding shareholders. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4618360 Tue, 22 Mar 2011 21:18:12 +0100 4618360 http://www.medworm.com/index.php?rid=4597391&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D733475%26tsource%3D3 LENEXA, KS (MARKET WIRE) Mediware Information Systems, Inc. (NASDAQ: MEDW) announced that Creative Testing Solutions (CTS) has selected the LifeTrak® software to manage blood testing procedures in the company's Tampa, Fla. location. The selection, which was the result of a thorough selection process including most major laboratory systems, expands Mediware's presence in the blood laboratory services industry and represents another major win for the modern and flexible LifeTrak software. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4597391 Wed, 16 Mar 2011 20:52:58 +0100 4597391 http://www.medworm.com/index.php?rid=4597390&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D733366%26tsource%3D3 SAN FRANCISCO, CA (MARKET WIRE) Medivation, Inc. (NASDAQ: MDVN) today provided a corporate update and reported its financial results for the year ended December 31, 2010. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4597390 Wed, 16 Mar 2011 20:52:58 +0100 4597390 http://www.medworm.com/index.php?rid=4597389&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D733501%26tsource%3D3 FOSTER CITY, CA (MARKET WIRE) SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported preliminary results for the fourth quarter and year ended December 31, 2010. Revenues for the fourth quarter of 2010 grew to $23.6 million, or an increase of 30% compared to the fourth quarter of 2009. For the year ended December 31, 2010, total revenues grew to $85.1 million, or an 18% increase, compared with revenues of $72.4 million for the year ended December 31, 2009. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4597389 Wed, 16 Mar 2011 20:52:58 +0100 4597389 http://www.medworm.com/index.php?rid=4597388&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D733441%26tsource%3D3 BOTHELL, WA (MARKET WIRE) Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that it will host a conference call with investors and security analysts on Wednesday, March 23, 2011, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to provide a business update and discuss financial results for the fourth quarter and fiscal year ended December 31, 2010. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4597388 Wed, 16 Mar 2011 20:52:58 +0100 4597388 http://www.medworm.com/index.php?rid=4585297&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D732849%26tsource%3D3 LOS ANGELES, CA (MARKET WIRE) Officials at Cleveland Biolabs (NASDAQ: CBLI) continue to monitor the situation in Japan as U.S. Navy personnel have begun taking precautionary measures after instruments aboard an aircraft carrier docked in Japan detected some levels of radioactivity from the Fukushima Daiichi nuclear plant. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4585297 Tue, 15 Mar 2011 17:42:48 +0100 4585297 http://www.medworm.com/index.php?rid=4585296&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D732856%26tsource%3D3 TUCSON, AZ (MARKET WIRE) SynCardia Systems, Inc. announced today that the longest running health and wellness series on public television, "Healthy Body, Healthy Mind" has produced a 30-minute program featuring the world's first and only FDA, Health Canada and CE approved Total Artificial Heart: the SynCardia temporary Total Artificial Heart. The program, titled "Saving Lives with the Total Artificial Heart" can be viewed by clicking here: http://www.syncardia.com/News/healthy-body-healthy-mind-on-public-broadcasting-pbs.html (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4585296 Tue, 15 Mar 2011 17:42:48 +0100 4585296 http://www.medworm.com/index.php?rid=4556491&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D730105%26tsource%3D3 COHASSET, MA (MARKET WIRE) Conihasset Capital Partners, Inc. (PINKSHEETS: CNHA) (the "Company") has announced that on March 4, 2011 Edward M. Mulherin, CPA was appointed Chief Financial Officer of the Company. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4556491 Tue, 08 Mar 2011 16:31:00 +0100 4556491 http://www.medworm.com/index.php?rid=4542171&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D728511%26tsource%3D3 NEW YORK, NY (MARKET WIRE) MedLink (PINKSHEETS: MLKNA) (OTCQB: MLKNA), a leading provider of clinical software and healthcare IT solutions, along with Secure EDI, a leading provider of electronic claims solutions and healthcare IT services for payers and providers announced today the launch of its collaboration to offer Secure EMR to the Puerto Rican market. Secure EMR 4.0, a product co-developed by MedLink and Inmediata Health Group Corporation, Puerto Rico's leading healthcare EDI exchange and a subsidiary of Secure EDI, will be marketed as a fully integrated EHR, Practice Management and electronic claims (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4542171 Thu, 03 Mar 2011 20:20:00 +0100 4542171 http://www.medworm.com/index.php?rid=4503996&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D724258%26tsource%3D3 DULUTH, GA (MARKET WIRE) Sam Mikhail, vice president of sales at ACOM Health, is pleased to announce the appointment of Dr. David Speakman as a regional manager of the company's ONC-ATCB 2011/2012 Certified RAPID Chiropractic Software sales team. Dr. Speakman, a veteran chiropractor, operated a multidisciplinary clinic in Thousand Oaks, California for 20 years before transitioning to the business world, and operates from his offices in Sandpoint, Idaho. ACOM Health now has six chiropractors staffing positions throughout the company. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4503996 Tue, 22 Feb 2011 19:36:00 +0100 4503996 http://www.medworm.com/index.php?rid=4485890&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D722916%26tsource%3D3 TIRAT CARMEL, ISRAEL (MARKET WIRE) D. Medical Industries Ltd. (NASDAQ: DMED)(TASE: DMED) ("D. Medical"), a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, announced today that, further to its press release of January 2, 2011, its publicly held subsidiary, NextGen Biomed Ltd. ("NextGen"), will not proceed with its previously planned acquisition of the shares of ClearPath Ltd and Innosense Ltd, two privately held Israeli companies engage in the functional food and beverage industry (the (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4485890 Thu, 17 Feb 2011 19:54:00 +0100 4485890 http://www.medworm.com/index.php?rid=4456933&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D719759%26tsource%3D3 VANCOUVER, BRITISH COLUMBIA (MARKET WIRE) Imperial Ginseng Products Ltd. (TSX VENTURE: IGP)(TSX VENTURE: IGP.PR.A) ("Imperial") is pleased to announce that it has obtained approval from the TSX Venture Exchange for the consolidation of two share classes. The post-consolidation common shares and convertible preference shares, Series "A" will commence trading on the TSX Venture Exchange on Friday, February 11, 2011. The trading symbol for each share class remains unchanged. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4456933 Thu, 10 Feb 2011 19:36:00 +0100 4456933 http://www.medworm.com/index.php?rid=4447488&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D718380%26tsource%3D3 ALEXANDRIA, VA (MARKET WIRE) New data released last week from the Centers for Disease Control and Prevention (CDC) paint an urgent picture of the state of diabetes, estimating that nearly 26 million children and adults in the United States are now living with diabetes. With one out of every three Americans at high risk for type 2 diabetes, emphasis must be placed on prevention and lifestyle modifications that can delay or prevent type 2 diabetes, a debilitating disease that can lead to blindness, kidney failure, heart disease and death. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4447488 Tue, 08 Feb 2011 19:00:00 +0100 4447488 http://www.medworm.com/index.php?rid=4443336&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D717749%26tsource%3D3 LAS VEGAS, NV (MARKET WIRE) Elsevier Business Intelligence, the medtech industry's leading provider of strategic business intelligence and partnership investment conferences, will host 'IN3 West' on Feb. 22-24, 2011, at The Venetian Resort-Hotel-Casino, Las Vegas. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4443336 Mon, 07 Feb 2011 19:35:00 +0100 4443336 http://www.medworm.com/index.php?rid=4443337&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D717759%26tsource%3D3 NEW YORK, NY (MARKET WIRE) Tomorrow's laboratories will utilize advanced diagnostic and information management technologies, such as digital pathology and molecular studies. They will require sophisticated, fast, easy-to-use and most importantly interoperable laboratory information systems (LIS) to handle the resulting more complex and high volume data, says a new report from healthcare market research publisher Kalorama Information, "Laboratory Information Systems (LIS / LIMS) Markets," which estimates that the market for LIS in the clinical laboratory will grow in the 6% range annually in the next few years from $800 (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4443337 Mon, 07 Feb 2011 19:31:00 +0100 4443337 http://www.medworm.com/index.php?rid=4430467&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D716629%26tsource%3D3 SAN FRANCISCO, CA (MARKET WIRE) Resilient Network Systems announced today that former Epocrates CEO, Kirk Loevner, recently joined as the company's Chief Executive Officer. Loevner is an innovative leader with a proven track record for successfully leading the growth of multiple start-up companies. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4430467 Thu, 03 Feb 2011 20:10:00 +0100 4430467 http://www.medworm.com/index.php?rid=4430468&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D716639%26tsource%3D3 MONTREAL, QUEBEC (MARKET WIRE) A5 Laboratories Inc. (A5 Labs) (OTCBB: AFLB) announced today the office of Biohazard and Containment Safety in their letter dated February 1, received on February 2 stated the office has received and reviewed the inspection checklist for the animal Pathogen Containment Level 2 at our facility in Lachine and found them acceptable for work in vitro. We will be waiting for another approval from the authorities before being able to work in pathogen agent at our laboratories. This is pathogen like E.Coli, and some other bacteria will be needed to be used as standard in our CRO laboratories. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4430468 Thu, 03 Feb 2011 19:23:00 +0100 4430468 http://www.medworm.com/index.php?rid=4421296&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D715201%26tsource%3D3 LONDON, ENGLAND (MARKET WIRE) Lightlake Therapeautics ("Lightlake") (OTCBB: LLTP) After the recent FDA decision concerning Orexigen's obesity medicine, Contrave(TM) (naltrexone plus bupropion) Lightlake would like to clarify that they do not anticipate the same cardiovascular problems with their treatment of binge eating disorder with naloxone alone. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4421296 Tue, 01 Feb 2011 19:02:00 +0100 4421296 http://www.medworm.com/index.php?rid=4421297&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D715182%26tsource%3D3 LAVAL, QUEBEC (MARKET WIRE) LAB Research Inc. ("LAB Research" or the "Company") (TSX: LRI), a Canadian-based global non-clinical contract research organization, today announced it has secured additional support from its main Canadian lender to enable the completion of the strategic review process initiated in October 2010 (the "Strategic Process"). (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4421297 Tue, 01 Feb 2011 18:36:00 +0100 4421297 http://www.medworm.com/index.php?rid=4421298&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D715169%26tsource%3D3 LONDON, ENGLAND (MARKET WIRE) Lightlake Therapeautics ("Lightlake") (OTCBB: LLTP) After the recent FDA decision concerning Orexigen's obesity medicine, Contrave(TM) (naltrexone plus bupropion) Lightlake would like to clarify that they do not anticipate the same cardiovascular problems with their treatment of binge eating disorder with naloxone alone. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4421298 Tue, 01 Feb 2011 18:22:00 +0100 4421298 http://www.medworm.com/index.php?rid=4416213&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D714516%26tsource%3D3 PHOENIX, AZ (MARKET WIRE) MedShape Weight Loss Clinic, a national leader in safe and effective weight loss, announced today its strong endorsement of the Food and Drug Administration (FDA) statement released on Jan. 24, 2011 calling for the immediate cease of the marketing and sale of "Homeopathic HCG" formulations. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4416213 Mon, 31 Jan 2011 18:51:00 +0100 4416213 http://www.medworm.com/index.php?rid=4416214&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D714514%26tsource%3D3 EVERETT, WA (MARKET WIRE) 2011 AHR Expo Booth #C838 -- As technicians describe their expectations for 2011, Fluke Corporation, the global leader in portable electronic test and measurement technology, is already responding, showcasing six new products at the 2011 AHR Expo in Las Vegas, all designed for new-market specifications. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4416214 Mon, 31 Jan 2011 18:47:00 +0100 4416214 http://www.medworm.com/index.php?rid=4408190&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D713967%26tsource%3D3 LEIDEN, NETHERLANDS (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4408190 Fri, 28 Jan 2011 18:56:00 +0100 4408190 http://www.medworm.com/index.php?rid=4391149&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D712094%26tsource%3D3 IRVINE, CA (MARKET WIRE) The recently launched Cure Cystinosis International Registry (www.cystinosisregistry.org) has been translated into Spanish, dramatically increasing the accessibility of the CCIR, which is the first global effort to link cystinosis patients with scientists and researchers who are developing new treatments. The rare metabolic and fatal disorder afflicts about 2,000 persons, mostly children, worldwide. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4391149 Tue, 25 Jan 2011 01:02:00 +0100 4391149 http://www.medworm.com/index.php?rid=4374452&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D710809%26tsource%3D3 AMSTERDAM, THE NETHERLANDS and BRIDGEWATER, NJ (MARKET WIRE) Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, and Axcan Holdings, Inc., a leading pharmaceutical company focused on the treatment of gastrointestinal disorders, announced the extension of the expiration date of the offer of Axcan Pharma Holding B.V. to purchase all of the outstanding ordinary shares of Eurand N.V. (the "Tender Offer"). The Tender Offer is now scheduled to expire at 12:01 a.m., New York City time, on February 3, 2011, unless further extended or earlier terminated. As of 12:00 p.m., New York City time today, a total of 38,546,690 shares, or (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4374452 Thu, 20 Jan 2011 18:52:00 +0100 4374452 http://www.medworm.com/index.php?rid=4357733&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D709354%26tsource%3D3 ALEXANDRIA, VA (MARKET WIRE) Last year, the passage of the Patient Protection and Affordable Care Act was a historic moment for people with diabetes and for those at risk for diabetes. That's because of provisions in the law that provide for quality, affordable diabetes care and diabetes prevention. But it wasn't without controversy and struggle. As the debate heats up again, we want to ensure that Members of Congress understand the truth about health reform and the provisions that bear upon diabetes. For the nearly 24 million people living with diabetes, it is essential that insurers are not able to refuse to sell or (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4357733 Tue, 18 Jan 2011 15:47:00 +0100 4357733 http://www.medworm.com/index.php?rid=4339985&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D708136%26tsource%3D3 NEW YORK, NY (MARKET WIRE) The market for point-of-care (POC) tests has almost doubled in size from 2003 to 2009, according to a new report published by Kalorama Information. With the ability to help reduce healthcare costs while simultaneously improving patient care, POC tests represent a significant and growing share of the world in vitro diagnostics (IVD) market. The findings from the healthcare market research publisher's report "Worldwide Point of Care Diagnostic Test Markets" value the market for combined OTC and professional applications of POC testing at $13.3 billion worldwide in 2009. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4339985 Thu, 13 Jan 2011 19:31:00 +0100 4339985 http://www.medworm.com/index.php?rid=4339986&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D708132%26tsource%3D3 ALEXANDRIA, VA (MARKET WIRE) The American Diabetes Association®, the nation's leading voluntary health organization in the fight to Stop Diabetes®, is pleased to honor Senator Al Franken (D-MN) with the 2010 Distinguished Leadership in Diabetes Policy Award. The award will be presented at an upcoming event held January 14, 2011. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4339986 Thu, 13 Jan 2011 19:29:00 +0100 4339986 http://www.medworm.com/index.php?rid=4333925&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D707617%26tsource%3D3 SANTA CLARA, CA (MARKET WIRE) The International Society for Quality Electronic Design (ISQED) today announced that Joseph Sawicki, vice president and general manager of the Design-to-Silicon division of Mentor Graphics Corporation (NASDAQ: MENT), has joined the group's Strategic Steering Committee. Mr. Sawicki is a leading expert in IC nanometer design and manufacturing challenges, and is responsible for Mentor's design-to-silicon products, including the Calibre® physical verification, DFM and RET/OPC platform, and the Mentor® Tessent™ design-for-test product line. The ISQED Strategic Steering Committee (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4333925 Wed, 12 Jan 2011 19:42:00 +0100 4333925 http://www.medworm.com/index.php?rid=4333926&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D707638%26tsource%3D3 ATLANTA, GA (MARKET WIRE) QuickCutCNC™ (http://www.QuickCutCNC.com), the new rapid CNC machining service recently released by custom manufacturing leader Quickparts (http://www.quickparts.com), has announced the launch of a new interactive 3D design for manufacturability (DFM) viewer that is available with every quote. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4333926 Wed, 12 Jan 2011 19:33:00 +0100 4333926 http://www.medworm.com/index.php?rid=4315495&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D705722%26tsource%3D3 OTTAWA, ONTARIO (MARKET WIRE) Chemaphor Inc. (TSX VENTURE: CFR), today announced that it will issue a total of 4,721,132 common shares in satisfaction of $380,000 in principal and $24,903 in interest accrued to December 31, 2010 on convertible debentures issued by Chemaphor on April 30, 2009. This issuance will satisfy Chemaphor's obligations under those debentures and result in their cancellation. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4315495 Thu, 06 Jan 2011 21:00:00 +0100 4315495 http://www.medworm.com/index.php?rid=4311200&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D705120%26tsource%3D3 PARSIPPANY, NJ (MARKET WIRE) The Medicines Company (NASDAQ: MDCO) will present at the 29th Annual JP Morgan Healthcare Conference on Tuesday, January 11th, in San Francisco, beginning at 3:00pm Pacific Standard Time, 6:00pm Eastern Standard Time. Clive A. Meanwell, Chairman and Chief Executive Officer, will provide a company overview and outlook in the presentation. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4311200 Wed, 05 Jan 2011 21:30:00 +0100 4311200 http://www.medworm.com/index.php?rid=4306751&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D704687%26tsource%3D3 PRINCETON, NJ (MARKET WIRE) Agile Therapeutics, a pharmaceutical company focused on developing and commercializing more convenient women's contraceptive products, announced the company will present at the Biotech Showcase 2011 at the Parc 55 Wyndham San Francisco Hotel in San Francisco, CA. Agile's President & CEO, Al Altomari, is scheduled to present an overview of the company on Wednesday, January 12, 2011 at 4:15 pm PT (7:15 pm ET). (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4306751 Tue, 04 Jan 2011 19:49:00 +0100 4306751 http://www.medworm.com/index.php?rid=4306752&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D704691%26tsource%3D3 NEW YORK, NY (MARKET WIRE) Device innovations, demographics and hospital austerity will drive the global medical device market over $300 billion, according to healthcare market research publisher Kalorama Information. In its report, "The Global Market for Medical Devices," Kalorama Information's analysts presage a $312 billion medical device market in 2011. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4306752 Tue, 04 Jan 2011 19:43:00 +0100 4306752 http://www.medworm.com/index.php?rid=4283079&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D703150%26tsource%3D3 NANCHANG, CHINA (MARKET WIRE) Hiru Corporation (PINK SHEETS: HIRU) (www.hirucorporation.com) launches Jiangxi Fisheries Biology Co. to continue expansion into aquaculture. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4283079 Thu, 23 Dec 2010 20:45:00 +0100 4283079 http://www.medworm.com/index.php?rid=4276600&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D702389%26tsource%3D3 LONDON and SOUTH SAN FRANCISCO, CA (MARKET WIRE) GlaxoSmithKline (GSK) and Theravance (NASDAQ: THRX) announced today that the first patient has started treatment with an investigational inhaled bifunctional compound GSK961081 ('081) in a Phase IIb study to evaluate efficacy and safety in patients with moderate to severe chronic obstructive pulmonary disease (COPD). (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4276600 Tue, 21 Dec 2010 21:05:00 +0100 4276600 http://www.medworm.com/index.php?rid=4243489&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D697484%26tsource%3D3 NEW YORK CITY, NY (MARKET WIRE) Optigenex Inc. (PINKSHEETS: OPGX) the "Company" today announced that effective as of December 8, 2010, the Finra has cleared a 1-for-125 reverse split of the Company's issued and outstanding common stock. As a result of the reverse stock split, the Company's secured lender will issue a waiver with respect to all defaults under Debentures held by the secured lender until December 31, 2012. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4243489 Thu, 09 Dec 2010 20:04:00 +0100 4243489 http://www.medworm.com/index.php?rid=4243490&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D697482%26tsource%3D3 VANCOUVER, BRITISH COLUMBIA (MARKET WIRE) Sirona Biochem Corp. (TSX VENTURE: SBM) (the "Company"), a biotechnology company specializing in carbohydrate-based molecules, including therapeutics for diabetes and obesity, cosmeceuticals and biological ingredients, announced today that it hired Dynamo Consulting Group Inc. and Capital Acceleration Fund Limited to assist in corporate development services. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4243490 Thu, 09 Dec 2010 19:33:00 +0100 4243490 http://www.medworm.com/index.php?rid=4239808&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D696702%26tsource%3D3 CALGARY, ALBERTA (MARKET WIRE) Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or the "Company") is pleased to announce today that it has been granted a patent by the U.S. Patent and Trademark Office -U.S. Patent 7,846,898- entitled, "Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis." The claims cover the use of luteinizing hormone (LH) or human chorionic gonadotrophin (hCG) and erythropotein (EPO) for producing neural stem cells (in vitro & in vivo), which can in turn produce more neurons or glial cells to compensate for lost (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4239808 Wed, 08 Dec 2010 20:03:00 +0100 4239808 http://www.medworm.com/index.php?rid=4235265&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D695980%26tsource%3D3 BEDFORD, MA (MARKET WIRE) Insulet Corporation (NASDAQ: PODD) today announced the sale of 3,000,000 shares of its common stock pursuant to an underwriting agreement with Canaccord Genuity Inc. acting as the sole bookrunner. The last reported sale price of Insulet's common stock as reported by the Nasdaq Global Market on December 7, 2010 was $14.42 per share. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4235265 Tue, 07 Dec 2010 21:11:00 +0100 4235265 http://www.medworm.com/index.php?rid=4222661&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D693999%26tsource%3D3 CAMBRIDGE, MA (MARKET WIRE) Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), a biopharmaceutical company discovering and developing targeted therapeutic and imaging radiopharmaceuticals for use in oncology, today announced that the Company has received a further extension of its waiver agreement with its Bond holders, allowing debt restructuring discussions to continue. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4222661 Fri, 03 Dec 2010 00:38:00 +0100 4222661 http://www.medworm.com/index.php?rid=4210476&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D692450%26tsource%3D3 BUFFALO, NY (MARKET WIRE) Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that CBLB502, a drug under development to treat exposure to radiation, has been granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4210476 Tue, 30 Nov 2010 16:25:00 +0100 4210476 http://www.medworm.com/index.php?rid=4177095&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D688171%26tsource%3D3 LANSING, MI (MARKET WIRE) Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announces that the Company has submitted its 10Q filing for the third quarter of 2010. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4177095 Thu, 18 Nov 2010 11:05:00 +0100 4177095 http://www.medworm.com/index.php?rid=4173570&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D687556%26tsource%3D3 TUSTIN, CA, and ORLANDO, FL (MARKET WIRE) Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced preclinical data demonstrating its lead antibody bavituximab's ability to bind to virus particles and virus-infected cells of five viruses that cause viral hemorrhagic fever (VHF), including the highly lethal Ebola virus. Additionally, Peregrine reported bavituximab in combination with the antiviral drug ribavirin improved survival by up to 50% compared to either drug used as a monotherapy (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4173570 Wed, 17 Nov 2010 13:00:00 +0100 4173570 http://www.medworm.com/index.php?rid=4173569&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D686743%26tsource%3D3 SEATTLE, WA (MARKET WIRE) Pacific Biomarkers, Inc. (OTCBB: PBMC), a provider of biomarker laboratory services to the pharmaceutical, biotechnology and diagnostics industries, has responded to a recent report from the Centers for Disease Control projecting that as many as one in three adult Americans may suffer diabetes symptoms by the year 2050. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4173569 Wed, 17 Nov 2010 13:00:00 +0100 4173569 http://www.medworm.com/index.php?rid=4165654&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D686383%26tsource%3D3 LONDON, ONTARIO (MARKET WIRE) Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT) announced today that the Company will meet with several prospective partners who have expressed an interest in its lead oncology drug candidate COTI-2 at Europe's largest pharmaceutical partnering conference, BIO-Europe, taking place in Munich, Germany on November 15-17, 2010. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4165654 Mon, 15 Nov 2010 15:00:00 +0100 4165654 http://www.medworm.com/index.php?rid=4165653&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D685850%26tsource%3D3 BOTHELL, WA (MARKET WIRE) AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that the company is scheduled to present at the Maxim Group Growth Conference 2010 in New York City on Thursday, November 18 at 8:30 a.m. Eastern Time. J. David Boyle II, AVI's Interim President and Chief Executive Officer, and Chief Financial Officer, will provide a company overview. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4165653 Mon, 15 Nov 2010 15:00:00 +0100 4165653 http://www.medworm.com/index.php?rid=4165652&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D686038%26tsource%3D3 SAN DIEGO, CA (MARKET WIRE) Entest BioMedical Inc. (OTCBB: ENTB) announced today it has added Dr. Gregory McDonald to its Scientific Advisory Board (SAB). The Company views this as a major step in moving forward with its immuno-therapeutic cancer vaccine for dogs, as Dr. McDonald is a practicing veterinarian and typically treats more than 700 dogs per year that have various forms of cancer. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4165652 Mon, 15 Nov 2010 15:00:00 +0100 4165652 http://www.medworm.com/index.php?rid=4165655&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D686351%26tsource%3D3 BOSTON, MA (MARKET WIRE) Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) provided its shareholder with supplemental information on the $0.97 per share buyout offer. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4165655 Mon, 15 Nov 2010 14:35:00 +0100 4165655 http://www.medworm.com/index.php?rid=4165656&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D686360%26tsource%3D3 VANCOUVER, BRITISH COLUMBIA (MARKET WIRE) Global Health Ventures Inc. (OTCBB: GHLV) (the "Company") is pleased to announce that it has reached a critical milestone in the development of its lead male sexual enhancement drug, X-Excite. The Company has now filed its application for approval with the European regulatory agency to carry out the initial phase of bioequivalent study in man. The current study is expected to take 3-4 months. This is a major stepping stone for the company's lead product X-Excite. After the completion of these trials, the Company will be in a strong position to enter into partnership with major (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4165656 Mon, 15 Nov 2010 14:25:00 +0100 4165656 http://www.medworm.com/index.php?rid=4153696&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D685167%26tsource%3D3 LEIDEN, NETHERLANDS (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4153696 Thu, 11 Nov 2010 06:41:00 +0100 4153696 http://www.medworm.com/index.php?rid=4136927&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D682899%26tsource%3D3 NORTHBROOK, IL (MARKET WIRE) Horizon Pharma, Inc., a biopharmaceutical company developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases, today announced that on November 4, 2010, the FDA Gastrointestinal (GI) Drugs Advisory Committee voted in favor that endoscopically diagnosed upper GI ulcers are an adequate primary endpoint for evaluating products intended to reduce the risk of NSAID-induced upper GI toxicity. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4136927 Fri, 05 Nov 2010 23:01:11 +0100 4136927 http://www.medworm.com/index.php?rid=4136926&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D682915%26tsource%3D3 BURNABY, BRITISH COLUMBIA (MARKET WIRE) Lifebank Corp. ("Lifebank" or the "Company") (TSX VENTURE: LBK) announced today the appointment of Jeff Charpentier as Chief Financial Officer. Mr. Charpentier assumes his new role effective November 5, 2010. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4136926 Fri, 05 Nov 2010 23:01:11 +0100 4136926 http://www.medworm.com/index.php?rid=4123098&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D680314%26tsource%3D3 BERKELEY, CA (MARKET WIRE) Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the Oppenheimer 21st Annual Healthcare Conference on Tuesday, November 2, 2010 at 10:15 am EDT (7:15 am PDT) at the Waldorf Astoria Hotel in New York. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4123098 Mon, 01 Nov 2010 17:05:07 +0100 4123098 http://www.medworm.com/index.php?rid=4123097&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D679570%26tsource%3D3 MONTREAL, QUEBEC (MARKET WIRE) ethica Clinical Research Inc. ("ethica"), a Contract Research Organization (CRO) headquartered in Montreal, has established operations of its non-profit ethics review division, Veritas IRB, in Mexico City in order to provide ethics review services in Mexico and Central American countries. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4123097 Mon, 01 Nov 2010 17:05:07 +0100 4123097 http://www.medworm.com/index.php?rid=4113184&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D679864%26tsource%3D3 AURORA, ON (MARKET WIRE) Helix BioPharma Corp. (TSX: HBP) (NYSE Amex: HBP) (FRANKFURT: HBP) today announced financial results for the year ended July 31, 2010. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4113184 Fri, 29 Oct 2010 20:30:00 +0100 4113184 http://www.medworm.com/index.php?rid=4083950&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D675743%26tsource%3D3 NEW YORK, NY (MARKET WIRE) Interop New York Conference -- Interface Masters Technologies, an industry leader in high speed networking systems, today announced several new members of it's 10Gb Switch family. Niagara 2948 is the latest in high port density switching technology from Interface Masters, featuring 48 ports of 10G line-rate switching throughput in a 1U form factor. The system is fully manageable and is designed to integrate with Datacenter, Blade servers, Carrier Ethernet and Metro Ethernet devices, HPC clusters, enterprise storage systems, IT Security Appliances and Central Office applications. The system (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4083950 Wed, 20 Oct 2010 16:15:00 +0100 4083950 http://www.medworm.com/index.php?rid=4079825&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D674577%26tsource%3D3 IRVINE, CA (MARKET WIRE) SK&A, A Cegedim Company, a leading provider of healthcare Information solutions and research, today announced the addition of longtime information-industry sales professional David Simon to its management team as Senior Director of Sales. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4079825 Tue, 19 Oct 2010 16:00:00 +0100 4079825 http://www.medworm.com/index.php?rid=4075922&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D674300%26tsource%3D3 CENTERVILLE, MA (MARKET WIRE) UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that it has been selected as the only air purification medical device to be listed in the Infection Control Segment of the prestigious UK-based opinion and analysis industry publication "Public Service Review." In this, our second appearance for 2010, the Company offers an informative profile within the magazine as well as a full page back cover advertisement. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4075922 Mon, 18 Oct 2010 11:30:00 +0100 4075922 http://www.medworm.com/index.php?rid=4075925&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D673787%26tsource%3D3 COLUMBIA, SC (MARKET WIRE) BDI Pharma, Inc. (BDI), the nation's fastest growing national distributor of biotech therapies, announced that Sales Revenues for the first three (3) fiscal quarters of 2010 represented an increase of more than twenty-four percent (24%) compared with the same time period in 2009. The Specialty Biopharmaceutical class of products, specifically in the clinical area of Oncology, has grown more than six-fold over last year through the first nine (9) months of 2010. Also notable was continued growth within the Protein Biotherapeutics class, specific to the Hemophilia and Hyper-Immune product (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4075925 Mon, 18 Oct 2010 11:00:00 +0100 4075925 http://www.medworm.com/index.php?rid=4075924&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D674156%26tsource%3D3 PORTLAND, OR (MARKET WIRE) MolecularMD Corp. announced today that it has entered into a licensing agreement with New York University (NYU) and Memorial Sloan-Kettering Cancer Center (MSKCC). The agreement grants MolecularMD exclusive US commercial rights to patented intellectual property pertaining to the detection of the BRAF V600E mutation (US patent No. 7,442,507 B2). (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4075924 Mon, 18 Oct 2010 11:00:00 +0100 4075924 http://www.medworm.com/index.php?rid=4075923&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D674037%26tsource%3D3 TUSTIN, CA and SAN FRANCISCO, CA (MARKET WIRE) Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today reported interim data from an ongoing Phase II clinical trial of its novel brain cancer therapy Cotara®. Interim median overall survival was 86 weeks for a cohort of 14 patients with glioblastoma multiforme (GBM) treated at first relapse with a single infusion of Cotara. Cotara is a targeted monoclonal antibody linked to a radioisotope that is administered directly into the tumor, destroying the (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4075923 Mon, 18 Oct 2010 11:00:00 +0100 4075923 http://www.medworm.com/index.php?rid=4058099&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D672602%26tsource%3D3 CASTLE ROCK, CO (MARKET WIRE) AspenBio Pharma, Inc. (NASDAQ: APPY), today reported that the Company's Board of Directors has restructured AspenBio Pharma's governance to strategically focus the Company's resources in the most cost-effective manner, while retaining the experience and industry knowledge of its Board members. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4058099 Tue, 12 Oct 2010 20:35:00 +0100 4058099 http://www.medworm.com/index.php?rid=4058100&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D672609%26tsource%3D3 CALGARY, ALBERTA (MARKET WIRE) Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE: SSS) is pleased to announce that the company has recently received a request for a "full program proposal" for the NTx(R)-265 program in Traumatic Brain Injury (TBI). A pre-proposal submitted earlier for the Combat Casualty Program entitled "Regenerative Recovery After Traumatic Brain Injury" has been reviewed by the US Department of Defense and was deemed "of interest". (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4058100 Tue, 12 Oct 2010 20:30:00 +0100 4058100 http://www.medworm.com/index.php?rid=4054537&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D671513%26tsource%3D3 BOSTON, MA (MARKET WIRE) Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) announced today the official launch of its website with added investor relations tools. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4054537 Mon, 11 Oct 2010 13:30:00 +0100 4054537 http://www.medworm.com/index.php?rid=4054538&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D671785%26tsource%3D3 BERKELEY, CA (MARKET WIRE) Dynavax Technologies Corporation (NASDAQ: DVAX) today said that Dr. William L. Heyward, Vice President, Clinical Development, will make an oral presentation of new data from a subset of diabetes subjects evaluated as part of the company's previously reported multicenter, observer-blinded phase 3 study. The PHAST (Phase 3 HeplisAv Short-regimen Trial) study compared two doses of HEPLISAV (20µg HBsAg combined with 3000µg 1018 immunostimulatory sequence, Dynavax's Toll-like receptor agonist) given at 0 and 4 weeks (placebo at 24 weeks) to three doses of Engerix-B given at 0, 4 and 24 (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4054538 Mon, 11 Oct 2010 13:00:00 +0100 4054538 http://www.medworm.com/index.php?rid=4042788&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D671605%26tsource%3D3 VANCOUVER, BRITISH COLUMBIA (MARKET WIRE) WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX: WXI) announced today that Dr. Larry Gontovnick, WEX's Vice President, Research and Development has informed the Company of his intention to retire at the end of 2010. Dr. Gontovnick joined the Company as Senior Director, Clinical Development in September 2008 and was promoted to Vice President, Research and Development in March 2009. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4042788 Fri, 08 Oct 2010 17:40:00 +0100 4042788 http://www.medworm.com/index.php?rid=4020552&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D668887%26tsource%3D3 PHILLIPSBURG, NJ (MARKET WIRE) Mallinckrodt Baker will now be known as Avantor™ Performance Materials, company officials announced today as they unveiled a new name and identity following the recent acquisition by an affiliate of New Mountain Capital, a New York-based private equity investment firm. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4020552 Fri, 01 Oct 2010 17:27:00 +0100 4020552 http://www.medworm.com/index.php?rid=4020553&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D668860%26tsource%3D3 NEW YORK, NY (MARKET WIRE) Hearst Corporation announced today that Gregory H. Dorn, MD, MPH, has been named president of First DataBank, a subsidiary of Hearst Business Media. Dorn succeeds Donald M. Nielsen, MD, who has been appointed chairman of the First DataBank Advisory Board and senior health advisor. The appointments were announced today by Frank A. Bennack, Jr., vice chairman and CEO of Hearst Corporation, and Richard P. Malloch, president of Hearst Business Media, and are effective immediately. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4020553 Fri, 01 Oct 2010 17:00:00 +0100 4020553 http://www.medworm.com/index.php?rid=4015929&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D668239%26tsource%3D3 COLORADO SPRINGS, CO (MARKET WIRE) ADInstruments and Plato BioPharma have established a strategic training partnership agreement centered on in vivo pre-clinical research techniques. This partnership will provide advanced education courses with hands-on instruction in a state-of-the-art facility, featuring the latest in life science research equipment technologies. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4015929 Thu, 30 Sep 2010 17:00:00 +0100 4015929 http://www.medworm.com/index.php?rid=4015930&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D668511%26tsource%3D3 CORAL SPRINGS, FL (MARKET WIRE) Valiant Health Care, Inc. (OTCBB: VHCI) (PINKSHEETS: VHCI) announces that it has executed a term sheet with Atlantic Medical Supply, Inc., a Florida corporation ("AMS"), under which it will acquire all of the outstanding shares of AMS in exchange for cash, shares of Valiant's common stock and options to purchase shares of Valiant's common stock. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=4015930 Thu, 30 Sep 2010 16:57:00 +0100 4015930 http://www.medworm.com/index.php?rid=3971139&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D663131%26tsource%3D3 LUND, SWEDEN (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=3971139 Thu, 16 Sep 2010 06:37:00 +0100 3971139 http://www.medworm.com/index.php?rid=3971140&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D663125%26tsource%3D3 MARTINSRIED, GERMANY and MUNICH, GERMANY (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=3971140 Thu, 16 Sep 2010 06:11:00 +0100 3971140 http://www.medworm.com/index.php?rid=3944613&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D660257%26tsource%3D3 LUND, SWEDEN (MARKET WIRE) Active Biotech (NASDAQ OMX Nordic: ACTI) is scheduled to present at the Rodman & Renshaw 12th Annual Healthcare Conference on Tuesday, September 14 at the New York Palace Hotel in New York City, US. During the presentation, an update regarding Active Biotech's development programs will be provided. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=3944613 Thu, 09 Sep 2010 06:37:00 +0100 3944613 http://www.medworm.com/index.php?rid=3940785&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D659548%26tsource%3D3 LONDON (MARKET WIRE) StayinFront, Inc., a leading global provider of CRM and decision support solutions, announced today that its UK division has reached the shortlist for the Innovation in Action Award, an honor awarded top field marketing organizations by executives in the Consumer Goods Industry. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=3940785 Wed, 08 Sep 2010 07:00:00 +0100 3940785 http://www.medworm.com/index.php?rid=3937607&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D658970%26tsource%3D3 PARIS (MARKET WIRE) Cegedim Strategic Data, leading provider of integrated healthcare research, announces the results of its international Rep Quality Survey. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=3937607 Tue, 07 Sep 2010 06:30:00 +0100 3937607 http://www.medworm.com/index.php?rid=3923127&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D658221%26tsource%3D3 LEIDEN, NETHERLANDS (MARKET WIRE) Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it has converted all of the remaining January 2010 bonds. The current number of outstanding shares as per today is 355,781,497 from 347,979,345 at August 24, 2010. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=3923127 Thu, 02 Sep 2010 06:32:00 +0100 3923127 http://www.medworm.com/index.php?rid=3901481&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D655720%26tsource%3D3 STOCKHOLM, SWEDEN (MARKET WIRE) Swedish Orphan Biovitrum (STO: SOBI) today announced that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to Kineret(R) for the treatment of cryopyrin-associated periodic syndromes (CAPS). (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=3901481 Thu, 26 Aug 2010 06:40:00 +0100 3901481 http://www.medworm.com/index.php?rid=3883665&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D653951%26tsource%3D3 LONDON, UNITED KINGDOM (MARKET WIRE) A recent study found no evidence that a leading herbal poultry wormer had any effect on worm burdens in chickens. In fact the results were the same as if no treatment had been given at all. A third group of birds were treated with a conventional wormer, which proved to be 99% effective. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=3883665 Fri, 20 Aug 2010 07:00:00 +0100 3883665 http://www.medworm.com/index.php?rid=3856718&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D651133%26tsource%3D3 BAGSVAERD, DENMARK (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=3856718 Thu, 12 Aug 2010 07:21:00 +0100 3856718 http://www.medworm.com/index.php?rid=3856719&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D651134%26tsource%3D3 BAGSVAERD, DENMARK (MARKET WIRE) As part of the execution of Novo Nordisk A /S' DKK 8.5 billion share repurchase programme for 2010, a share repurchase programme has been initiated in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=3856719 Thu, 12 Aug 2010 07:08:00 +0100 3856719 http://www.medworm.com/index.php?rid=3852168&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D650654%26tsource%3D3 LUND, SWEDEN (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=3852168 Wed, 11 Aug 2010 06:42:00 +0100 3852168 http://www.medworm.com/index.php?rid=3838800&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D649057%26tsource%3D3 BRISTOL, TN (MARKET WIRE) King Pharmaceuticals, Inc. (NYSE: KG) (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=3838800 Mon, 09 Aug 2010 11:00:00 +0100 3838800 http://www.medworm.com/index.php?rid=3838802&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D649642%26tsource%3D3 SAN DIEGO, CA (MARKET WIRE) Cypress Bioscience, Inc. (NASDAQ: CYPB) today announced financial results for the second quarter of 2010. The Company reported total revenue of $9.1 million for the quarter ended June 30, 2010, which includes commercial revenues of $8.1 million and revenues under collaborative agreement of $0.8 million. For the quarter ended June 30, 2010, the Company reported a net loss of $1.8 million or $0.05 per share compared to a net loss of $8.6 million or $0.23 per share for the same period in 2009. At June 30, 2010, the Company had cash, cash equivalents and investments totaling $105.5 million. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=3838802 Mon, 09 Aug 2010 10:30:00 +0100 3838802 http://www.medworm.com/index.php?rid=3838801&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D649673%26tsource%3D3 TORONTO, ONTARIO (MARKET WIRE) BioExx Specialty Proteins Ltd. (TSX: BXI) is pleased to announce that it has successfully produced the world's first commercial-scale canola protein isolate, known as Isolexx(TM). The product was produced in the second full-scale protein run at the Saskatoon facility and was repeatedly tested in both the BioExx lab and at the independent testing facilities of POS Pilot Plant Corp. Average indicated purity at BioExx was 95.8% and the average at POS was 94.8%, with all other characteristics being similar to or better than the product from the recent initial protein run. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=3838801 Mon, 09 Aug 2010 10:30:00 +0100 3838801 http://www.medworm.com/index.php?rid=3825623&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D649262%26tsource%3D3 LEIDEN, NETHERLANDS (MARKET WIRE) OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery company, announces today its results for the six-month period ended 30 June 2010. (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=3825623 Fri, 06 Aug 2010 06:08:00 +0100 3825623 http://www.medworm.com/index.php?rid=3825624&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D649261%26tsource%3D3 LEIDEN, NETHERLANDS (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=3825624 Fri, 06 Aug 2010 06:04:00 +0100 3825624 http://www.medworm.com/index.php?rid=3825625&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D649260%26tsource%3D3 MECHELEN, BELGIUM (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=3825625 Fri, 06 Aug 2010 05:36:00 +0100 3825625 http://www.medworm.com/index.php?rid=3819285&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D648786%26tsource%3D3 TIRAT CARMEL, ISRAEL (MARKET WIRE) D. Medical Industries Ltd., (NASDAQ: DMED)(TASE: DMDC) a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, announced today the initial public offering in the United States of 1,500,906 of its ordinary shares at a price of US$7.00 per share. Prior to the initial public offering in the United States, the Company's ordinary shares were listed only in Israel on the Tel-Aviv Stock Exchange, or the TASE, under the symbol "DMDC". The Company's ordinary shares are now (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=3819285 Thu, 05 Aug 2010 06:11:00 +0100 3819285 http://www.medworm.com/index.php?rid=3819286&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D648783%26tsource%3D3 BAGSVAERD, DENMARK (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=3819286 Thu, 05 Aug 2010 06:04:00 +0100 3819286 http://www.medworm.com/index.php?rid=3808239&cid=s_22559_34_f&fid=22559&url=http%3A%2F%2Fwww2.marketwire.com%2Fmw%2Frelease_html_b1%3Frelease_id%3D647348%26tsource%3D3 MARTINSRIED, GERMANY and MUNCHEN, GERMANY (MARKET WIRE) (Source: Market Wire - Pharmaceuticals and Biotech) Market Wire - Pharmaceuticals and Biotech news http://www.medworm.com/rss/comments.php?id=3808239 Mon, 02 Aug 2010 05:37:00 +0100 3808239